News

Entinostat May Overcome AI Resistance in Breast Cancer


 

FROM A BREAST CANCER SYMPOSIUM SPONSORED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

"We are going to have more correlative work planned as a part of the phase-III trial that is coming up," Dr. Yardley added.

In an analysis that was exploratory because follow-up is still short, entinostat was also associated with better overall survival (26.9 vs. 20.3 months; HR, 0.56; P = .027). Additional data with longer follow-up will be reported at the San Antonio Breast Cancer Symposium later this year.

The combination of entinostat and exemestane was well tolerated, with no unexpected safety signals. The most common grade 3/4 adverse events in the entinostat group were fatigue (13%), neutropenia (13%), nausea (5%), and vomiting (5%). The rate of discontinuation because of adverse events was 1% in the placebo group and 11% in the entinostat group.

Dr. Yardley reported that she had no relevant conflicts of interest. Syndax Pharmaceuticals, developer of entinostat, was not among Dr. O’Shaughnessy’s disclosures.

Pages

Recommended Reading

Dual HER2 Blockade Strategies Advance in Breast Cancer Trials
MDedge Hematology and Oncology
Uncertainty Rules Adjuvant Chemo for Early HER2 Breast Cancer
MDedge Hematology and Oncology
U.K. Committee Calls Fulvestrant Unwise Use of Resources
MDedge Hematology and Oncology
Study Supports Palpation, Mammography Regardless of Age
MDedge Hematology and Oncology
New Nomograms Predict Lymphedema After Axillary Lymph Node Dissection
MDedge Hematology and Oncology
Breast Cancer Does Not Mandate Mastectomy in Young
MDedge Hematology and Oncology
Measure of Bone Metastases Predicts Breast Cancer Survival
MDedge Hematology and Oncology
FDA Panel: Update Bisphosphonate Labeling
MDedge Hematology and Oncology
Venlafaxine, Clonidine Top Placebo for Breast Cancer Hot Flashes
MDedge Hematology and Oncology
Molecular tumor profile: another consideration for postmastectomy radiotherapy
MDedge Hematology and Oncology